Two series of flavans were synthesized, the first substittued at 4' and/or 6 position with chlorine and cyano groups, and the second one with chlorine and/or oxazoline rings. The new compounds were tested in vitro against human rhinovirus 1B (HRV 1B) infection of HeLa cells by measuring the effect on the development of viral cytopathic effect and plaque formation. The compounds including both chlorine and cyano groups were the most active; 4'-(4,5-dihydro-2-oxazolyl)-6-chloroflavan was the most potent inhibitor among the oxazoline derivatives.
Introduction
Because of the high number of rhinovirus serotypes it is difficult, at present, to prepare a satisfactory vaccine against this group of viruses. For this reason, particular attention has been given to the development of agents effective in the prophylaxis or therapy of the common cold.
In searching for anti-rhinovirus compounds, we previously synthesized different series of halo, amidino and cyano flavans, isoflavans and 3(2H)-isoflavenes (Burali et al., 1987; Conti et al., 1990b) related to 4',6-dichloroflavan (BW683C) (Fig. 1) , which is the most potent inhibitor of rhinovirus infection in tissue culture systems yet described (Baueret sl., 1981) .All these new compounds were tested. against serotype 1B of rhinovirus, which was the most sensitive to the action of BW683C, to compare our results with those reported elsewhere (Bauer et sl., 1981) . All our compounds, with the exception of 4',6-dicyanoflavan, were less active than BW683C against rhinovirus 1B infection in vitro (Burali etal., 1987; Conti et al., 1990b) but, differently from BW683C which is inactive against the other picornaviruses (Bauer et al., 1981) , our compounds exhibited a broader spectrum, being active also against poliovirus type 2 (Conti et al., 1990a) , hepatitis A virus (Superti et el., 1989) , and astrovirus (Superti et aI., 1990) infection in vitro. At present no data are available for their therapeutic activity in vivo, while it is known that, in clinical trials, BW683C failed to protect against rhinovirus infection in man when orally (Phillpotts et al., 1983) or intranasally (AI-Nakib et al., 1987) administered.
Diana and colleagues have found high and broad spectrum antiviral activity in 5- [7-[4-(4,5- 
1) and in analogues phenoxyalkylisoxazoles Otto et al., 1985) . More recently 5-[5-[2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)-phenoxyj pentyl)3-methylisoxazole (WIN 54954) ( Fig. 1) was described as the most interesting one as an inhibitor of rhinovirus multiplication in vitro and of selected enteroviruses in vitro and in Vivo Woods et et., 1989) .
By considering the flavan structure, it can be noted that the phenoxyalkyl moiety is present also in this molecule, but in a constricted conformation.
On the basis of these observations, we synthesized new flavans substituted in 4' and/or 6 position with chloro and/or cyano groups or with the oxazoline ring (Fig. 2) .The presence of this last group is another common feature of some of our new compounds with the WIN series. In this study we describe a preliminary in vitro evaluation of their antiviral activity against the same rhinovirus serotype 1B previously used as a model.
Results

Chemistry
In a previous paper we described the preparation of the cyanoflavans V-VII by refluxing the corresponding bromoflavans with cuprous cyanide in N,N-dimethylforrnamide (Conti et aI., 1990b) . In the same conditions, starting from the chloro,bromoflavans I and II, the bromine atom only was substituted to give the chloro,cyanoflavans III and IV. The ethanolic solution of the nitriles III-VII was saturated with hydrochloric acid to obtain the corresponding iminoethers as hydrochlorides. These, after conversion to free bases, were heated with ethanolamine to give the corresponding oxazolines (VIII-XII). As already reported for CPE inhibition assay, III and IV were the most potent compounds, with an IC so value of 0.084 and 0.0085 ""M, respectively: IV was found to be about four-fold more active than the reference compound BW683C. The other compounds (VIII-X and XII) exhibited rather high inhibitory concentrations and compound XI had a very low specific activity, as defined by the ratio between the maximum non-toxic concentration and the IC so or MIC so value.
Effect of compounds on uninfected cells
In preliminary experiments the cytotoxicity of all the new synthesized nitriles and oxazolines was determined by evaluating the effect produced on HeLa (Ohio) cell morphology and viability over a 72 h exposure period.
The maximum non-toxic concentration (""M) of each compound is reported in Table 1 . The flavans III and XI were the least toxic compounds, while IV was the most toxic one. However, it must be pointed outthat in the case of compounds III, VIII, IX, XI and XII, the values could be even higher than those reported, because of their insolubility in aqueous solution at the next higher concentration.
Effect of compounds on HRV 1B cytopathogenicity
The activity of the compounds on HRV 1B multiplication in HeLa cell cultures was initially studied by examining the ability of various non-cytotoxic concentrations of each drug to interfere with the appearance of virus-induced cytopathic effect (CPE).
The results recorded at the 48th hour post-infection are reported in Fig. 3 (a,b ). All the drugs tested reduced the development of rhinovirus CPE; the 4 1 -chloro-6-cyanoflavan (IV)was found to be the most potent inhibitor of HRV multiplication. The minimal concentration of compounds reducing virus CPE by 50% (MIC so ), reported in Table 1 , ranged from 0.03 ""M to 40 ""M.
Effect of compounds on HRV 1B plaque formation
Measurement of the activity of isoflavans was also achieved. by means of plaque reduction assays. The incorporation of different amounts of the compounds into the agar overlay medium produced a dose-dependent reduction in rhinovirus plaque formation, as shown in Fig.  4 . In the conditions of the assay, the activity of BW683C, taken as reference compound, was found to be lower than reported by Bauer et al. (1981) . The concentration reducing the plaque number by 50% (IC so ) values of the flavans are displayed in Table 1 and have been calculated by plotting the percentage of plaque reduction against the logarithm of the compound dose, to yield a dose-response line from which the 50% inhibitory dose could be calculated (Fig. 4) .
.
Discussion
In the present paper we report the synthesis of a number of new anti-rhinovirus 1B compounds which show MIC and IC in the range of 4Q-0.03""M and 4.01-0.0085""M, respectively. At the active concentrations the compounds exhibited no toxicity towards the cell mono layers.
BW683C was taken as reference compound; in the conditions of the assay the activity of this product was found to be lower than reported elsewhere (Bauer et al., 1981) .
Among the newly tested compounds, 4 /-chloro-6-cyanoflavan (IV) was the only one to appear more active than BW683C. In plaque reduction assay, IV had an IC so of 0.0085 ""M, under assay conditions WhereBW683C had an IC so of 0.038 ""M. Therefore it is more than four times as active against HRV 1B as the reference compound.
The positive influence of chloro (Bauer et al., 1981) and cyano (Conti et al., 1990b) substituents on the activity of flavans has been noted previously; 4' ,6-dicyanoflavan (VII) has been already found to be the most effective compound of a series of analogues, With an IC so value of 0.023f.l.M in tissue culture (Gonti et al., 1990b) . The new results suggest, therefore, that the effect is higher in the presence of both the substituents, provided that the cyano group is in the 6 position. Two factors affected positively the activity in the oxazoline series: (i) the presence of a chlorine atom in the molecule and (ii) an oxazoline ring in its 4' position. In fact 4'-oxazolinyl-6-chloroflavan (VIII) was found to be the most potent inhibitor of this series; the IG so values of 4'-chloro-6-oxazolinylflavan (IX) and 4'-oxazolinylflavan (X) were similar, and 6-oxazolinylflavan (XI) was the least active (Table 1) .
The anti-picornavirus effect of related compounds such as WIN 51711 (Diana et aI., 1985; Otto et al., 1985) and WIN 54954 Woods et al., 1989) has already been described. In plaque reduction assays, WIN 51711 reduced plaque formation by nine enteroviruses and 33 rhinovirus serotypes, with IG so of 0.004-0.17 and 0.004-6.2 f.l.g rnr', respectively . The analogue WIN 54954 also reduced plaque formation of several enteroviruses and of 50 of 52 rhinovirus serotypes with MIG ranging from 0.007 to 2.2 f.l.g rnr' Woods et al., 1989) . In the case of HRV 1B, the 50% inhibitory concentration was reported to be 0.30 f.l.g mr', corresponding to 0.88 f.l.M for WIN 51711 , and 0.09 f.l.g rnr', corresponding to 0.24 f.l.M for WIN 54954 (Woods et al., 1989) . Therefore, the new oxazoline VIII (IG so = 0.29 f.l.M) was about three times more effective than WIN 51711 and approximately as equally active as WIN 54954.
However, the mechanism of action of the newly synthesized flavans has not yet been elucidated and more data a. Fivefold dilutions of the compounds in the culture medium were applied to the cells over a 72 h period. Cytotoxicity was scored as morphological alteration, e.g. rounding up, shrinking and detachment. The maximum non-toxic concentration was the dilution which did not produce any modification of cell morphology and viability. For compounds where > .... is indicated, the maximum non-toxic concentration was found to be higher than the saturation concentration in cell culture medium. b. The MIG50 value was the minimal concentration of the drug reducing virus GPE by 50% and was calculated by plotting the drug concentration versuS the percent reduction of CPE. c. The IC50 value was the concentration of compound reducing the plaque number by 50% and was calculated by plotting the drug concentration versus the percentage of plaque reduction. d. Conti et al. (1990b) .
Materials and Experimental procedures: chemistry
Melting points were determined in open glass capillaries on a BOchi SMP-20 apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer 297 instrument; NMR spectra on a Varian EM-390 90 MHz instrument, using tetramethylsilane as internal standard. The elemental analyses were within ±0.4% of theoretical values. We synthesized the haloflavans I and II according to a general method (Jurd, 1967) ; these products were patented (Batchelor et sl., 1979) , but in the patent the cyanoflavans were generically mentioned, and neither their chemical properties nor biological activity were described. The three cyanoflavans (V-VII) have been described previously by us (Conti et al., 1990b) . are necessary on the efficacy of this class of compounds, especially their range of activity against different rhinovirus serotypes and their action on other picornaviruses. These additional data are indispensable before envisaging in vivo studies, the results of which will give a definitive answer on the practical interest of all these compounds.
Synthesis of chloro,cyano derivatives (III, IV)
Cuprous cyanide (0.01 mol) was added to a solution of the chloro,bromo-compounds (lor II) (Bauer et al., 1981) (0.01 mol) in dry N,N-dimethylformamide (200ml) and the mixture was refluxed for 20 or 23h, respectively. After cooling, the suspension was diluted with water and filtered. The substance on the filter was washed with water and extracted with hot ethyl acetate; after evaporation under reduced pressure of the organic solvent, the product was crystallized from n-hexane (Tables 2 and 3) .
Synthesis of oxazolines (VIII-XII)
A solution of the cyanocompounds (III-VII) (0.01mol) in a mixture 1) was saturated with hydrochloric acid and left at room temperature. The reaction was followed by TLC until it was complete (average time 7 days).
Removal of the solvent under reduced pressure gave a solid residue that was triturated with ethyl ether and filtered. The crude iminoethers were solubilized in dichloromethane (400ml) and dry triethylamine (0.04 mol or 0.08 mol) was added. After stirring for 1 h, the solution was washed with water and dried over Na2S04'
The solvent was removed leaving a solid residue to which ethanolamine (0.04 mol or 0.08 mol) was added. The mixture was then heated at 120°C while stirring. At this point gas evolution (NH s) was observed. After 1.5 h the melted mixture was cooled and the excess of ethanolamine was evaporated under reduced pressure. The residue was crystallized from ethanol (Tables 2 and  3) .
Materials and Experimental procedures: virology
Cells and virus
HeLa (Ohio) cells were grown as monolayers in Eagle's minimal essential medium supplemented with 10% foetal bovine serum, antibiotics and glutamine. For cell maintenance the serum concentration was lowered to 2% (maintenance medium). Rhinovirus 1B was propagated in Hela cells which were infected at 0.5 to 1 plaque-forming units (PFU)/cell and incubated at 33°C until an extensive CPE was recorded. After centrifugation at low speed to remove cellular debris, the infectious supernatant was stored at -80°C.
Toxicity of compounds for uninfected cells
The drugs were dissolved in absolute ethanol to make stock solutions (1mg ml-' or 0.1 mg rnr') and subsequently diluted in the cell culture medium before use.
To determine the cytotoxic effect, confluent monolayers of HeLa cells in 96-well plates were exposed to serial five-fold dilutions of each drug in maintenance medium for 72 h at 33°C. Triplicate monolayers were utilized for each drug concentration. Cells were inspected daily to detect changes in cell morphology such as swelling, granularity, rounding or floating. The viability of the cells was determined by neutral red uptake at the third day of incubation,
Viral cytopathic effect inhibition assay
For CPE inhibition assay, confluent monolayers of HeLa cells in 24-well plates were infected with HRV 1B (1h, 33°C) in order to obtain a generalized CPE after 36-48 h of incubation at 33°C in control untreated infected cells. In drug-treated virus-infected wells, serial fivefold dilutions of the drugs were present during the virus adsorption period. After infection, the inoculum was decanted, the monolayers were rinsed twice with phosphatebuffered saline (PBS), pH 7.4, and added with maintenance medium containing the corresponding serial fivefold dilutions of the drugs. Triplicate monolayers were used for each drug concentration. The cells were scored microscopically for evidence of CPE each day and CPE recorded when virus controls (no drugs) showed 100% of cytopathogenic effect. The MIC so value was the concentration of drug reducing viral CPE by 50% when 100% of cells were destroyed by the virus in the control virus-infected cell monolayers; it was calculated by plotting the drug concentration versus the percent reduction of CPE.
Plaque assay
The plaque assay technique was essentially that of Fiala and Kenny (1966) . Briefly, monolayers of HeLa cells in 6-well plates were infected for 1h at 33°C with about 100 PFU of virus in the presence or absence of fivefold dilutions of drugs. After washing twice with PBS to remove unadsorbed virus, the monolayers were overlayed with medium with or without the corresponding concentration of compounds. After incubation for 72 h at 33°C in 5% CO 2, the cells were stained with neutral red (2h, 33°C) and the plaques counted. Three wells were utilized for each drug concentration and the mean value of plaque number was calculated. The IC so value was the amount of drug reducing the plaque number by 50% and was calculated by plotting the percentage of plaque reduction with respect to the control plaque count against the logarithm of compound dose to yield a dose-response line.
